The steroid 19-nortestosterone (nandrolone, 19-NT), popularized in esterified form as nandrolone decanoate (ND, Deca-durabolin or simply “Deca”), is an injectable synthetic anabolic-androgenic steroid (AAS) used in the strength and fitness community for building muscle. The traditional stack, hailed by “bro science” for over 40 years, combines ND with a testosterone ester such as testosterone cypionate or testosterone enanthate. The objective of the combination is to maximize the anabolic effects while keeping the adverse effects of supraphysiological use in check. ND and its relative safety as an anabolic agent has been addressed in the clinical context (48, 49) and for non-medical (i.e., athletic performance or cosmetic) use (see, e.g., past
The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart s pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology s 70th Annual Scientific Session.
1Department of Orthopeadics, The Affiliated Linfen Hospital of Shanxi Medical University, Linfen, Shanxi Province, People’s Republic of China;
2Department of Orthopeadics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Province, People’s Republic of China;
3Department of Orthopeadics, The Affiliated Shunde Hospital of Jinan University, Foshan, Guangdong Province, People’s Republic of China These authors contributed equally to this work
Correspondence: Xinghua Song
Department of Orthopeadics, The Affiliated Shunde Hospital of Jinan University, Foshan, 528303, People’s Republic of China
Zhen Wang
Department of Orthopeadics, The Affiliated Linfen Hospital of Shanxi Medical University, Linfen, 041000, People’s Republic of China
Operator
Welcome to the Ontrak first-quarter 2021 earnings call. My name is Sylvia and I ll be your operator for today s call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session.
[Operator instructions] I will now turn the call over to Caroline Paul, investor relations. Caroline you may begin.
Caroline Paul
Investor Relations
Thank you. And thank you all for participating in today s call. Joining me today are Terren Peizer, executive chairman; Jonathan Mayhew, chief executive officer; and Brandon LaVerne, chief financial officer. Earlier today, Ontrak released financial results for the quarter ended March 31, 2021.
Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021
News provided by
Share this article
Share this article
TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will be presented, including real-world evidence highlighting the impact of fatigue in U.S. adults with relapsing MS (RMS); a study assessing the impact of MS fatigue on work productivity and activity impairment; and cross-sectional analyses of both the economic and humanistic burden associated with fatigue in relapsing-remitting MS.